Stock Events

Novartis 

$110.18
1356
-$9.12-7.64% Friday 14:19

Statistics

Day High
115
Day Low
115
52W High
123.55
52W Low
90.24
Volume
100
Avg. Volume
17,087
Mkt Cap
244.08B
P/E Ratio
23.73
Dividend Yield
3.41%
Dividend
3.76

Upcoming

Dividends

3.41%Dividend Yield
10Y Growth
3.05%
5Y Growth
5.7%
3Y Growth
5.23%
1Y Growth
9.67%

Earnings

29OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
1.72
1.85
1.99
2.13
Expected EPS
1.908123
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVSEF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Pharmaceuticals: Major
Health Technology
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Show more...
CEO
Employees
76057
Country
CH
ISIN
CH0012005267

Listings